CN104189036B - Composition containing cerebroprotein hydrolysate and application of composition - Google Patents
Composition containing cerebroprotein hydrolysate and application of composition Download PDFInfo
- Publication number
- CN104189036B CN104189036B CN201410404033.2A CN201410404033A CN104189036B CN 104189036 B CN104189036 B CN 104189036B CN 201410404033 A CN201410404033 A CN 201410404033A CN 104189036 B CN104189036 B CN 104189036B
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- cerebrolysin vial
- compositions
- memory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a composition containing cerebroprotein hydrolysate and application of the composition. The composition comprises the following components in parts by weight: 10-12 parts of cerebroprotein hydrolysate, 6-8 parts of panax notoginseng saponins, 3-5 parts of ipratropium bromide and 1.5-2.5 parts of betadex. According to the composition containing cerebroprotein hydrolysate, the panax notoginseng saponins, the ipratropium bromide, the betadex and the cerebroprotein hydrolysate are firstly combined to achieve effects of improving the memory loss condition and strengthening the memory by virtue of proper proportion regulation, and can be used for preparing a drug or a health product for strengthening the memory.
Description
Technical field
The present invention relates to new drug development technical field, be specifically related to the medicine of memory reinforcing.
Background technology
Improving human-subject test is that the mankind constantly pursue, especially in modern society, along with sharply increase and the renewal of various information, no matter be that student or adult need constantly to grasp increasing knowledge and skill, therefore, the product that exploitation effectively strengthens human memory's power is very important, and has wide market prospect.
Cerebrolysin Vial is the low molecular peptide class Neurotrophic drugs prepared through modern biotechnology enzymatic degradation technology by health pig cerebral tissue; low molecular peptide has biological activity; the metabolism of human body brain, neurotransmission and nerve growth can be regulated; breakdown of glucose enzymatic activity can be improved; increase brain to the anaerobic energy metabolism of glucose; reduce the concentration of lactic acid in brain, have protective effect when hypoxic-ischemic to the mitochondrion of neurocyte.
Radix Notoginseng total arasaponins, molecular formula is C
47h
80o
17, be pale yellow powder, cure mainly blood circulation promoting and blood stasis dispelling, promote blood circulation active.There is the effect of anticoagulant and increase cerebral blood flow, for cerebrovascular sequelae, central retinal vein occlusion, hyphema etc.
Ipratropium bromide, structural formula, as shown in formula I, is white crystalline powder; Ipratropium bromide a kind ofly has potent anticholinergic agent compared with high selectivity to bronchial smooth muscle, and lax bronchial smooth muscle effect is stronger.
Betacyclodextrin is white crystals or crystalline powder.
At present, there is not yet the research being used for Radix Notoginseng total arasaponins, ipratropium bromide to strengthen human body memory medicine aspect, be also used for there are no by Radix Notoginseng total arasaponins, ipratropium bromide, betacyclodextrin collocation Cerebrolysin Vial the relevant report strengthening human body memory medicine aspect.
Summary of the invention
The object of this invention is to provide a kind of human body memory that strengthens, containing the compositions of Cerebrolysin Vial.
Another object of the present invention is to provide the preparation method of above-mentioned composition.
Another object of the present invention is to provide the application of above-mentioned composition in the medicine of preparation enhancing human body memory.
Above-mentioned purpose of the present invention is achieved by following scheme:
Containing a compositions for Cerebrolysin Vial, said composition is made up of each component of following parts by weight:
The preferred version of above-mentioned composition is as follows:
The preparation method of the above-mentioned compositions containing Cerebrolysin Vial is as follows:
Cerebrolysin Vial, Radix Notoginseng total arasaponins, ipratropium bromide and betacyclodextrin to be ground respectively and after crossing 100 mesh sieves, after the mixing of formula consumption, put into dry 30 minutes of the baking oven of 55-65 DEG C, then prepare the compositions containing Cerebrolysin Vial of the present invention.
The above-mentioned compositions containing Cerebrolysin Vial can make various dosage form with pharmaceutically acceptable carrier or excipient, as tablet, granule, capsule or injection etc.
Compositions containing Cerebrolysin Vial of the present invention is through experimentation, and it can the situation of Improving memory power decline, and memory reinforcing, therefore, can be used for the medicine preparing memory reinforcing.
Compared with prior art, the present invention has following beneficial effect:
1. the compositions containing Cerebrolysin Vial of the present invention, first Radix Notoginseng total arasaponins, ipratropium bromide and betacyclodextrin are introduced in the drugs improving human body memory, by these three kinds of material collocation Cerebrolysin Vials, allocated by suitable ratio, serve Improving memory power decline situation well, effect of memory reinforcing;
2. the compositions containing Cerebrolysin Vial of the present invention, in its formula, each composition is all that basic research and clinical practice confirm do not have obvious toxic-side effects, and does not have the taboo of compatibility between each composition, without mutual ill effect, therefore has safety.
Detailed description of the invention
Below in conjunction with specific embodiment the present invention done and describe further, but specific embodiment does not do any restriction to the present invention.
Embodiment 1
Containing a compositions for Cerebrolysin Vial, the formula of said composition is made up of each component of following parts by weight:
The preparation method of the above-mentioned compositions containing Cerebrolysin Vial is as follows:
Cerebrolysin Vial, Radix Notoginseng total arasaponins, ipratropium bromide and betacyclodextrin to be ground respectively and after crossing 100 mesh sieves, after the mixing of formula consumption, put into dry 30 minutes of the baking oven of 55-65 DEG C, then prepare the compositions containing Cerebrolysin Vial of the present embodiment.
Embodiment 2
The present embodiment containing the compositions of Cerebrolysin Vial, except the consumption of each component in formula is different from embodiment 1, all the other are all identical with embodiment 1, and the formula of the present embodiment compositions is made up of each component of following parts by weight:
Embodiment 3
The present embodiment containing the compositions of Cerebrolysin Vial, except the consumption of each component in formula is different from embodiment 1, all the other are all identical with embodiment 1, and the formula of the present embodiment compositions is made up of each component of following parts by weight:
Comparative example 1
The formula of this comparative example compositions is made up of each component of following parts by weight:
Radix Notoginseng total arasaponins 7 parts;
Ipratropium bromide 4 parts;
Betacyclodextrin 2 parts.
The preparation method of this comparative example compositions is as follows:
Radix Notoginseng total arasaponins, ipratropium bromide and betacyclodextrin to be ground respectively and after crossing 100 mesh sieves, after the mixing of formula consumption, put into dry 30 minutes of the baking oven of 55-65 DEG C, then prepare the compositions of comparative example.
The understanding experiment of embodiment 4 healthy rat
The public Mus 60 that experiment 10 week of use is large, experimental mouse is divided into 6 groups at random, often organizes 10, shown in specific as follows:
(1) blank group: feeding saline solution;
(2) experimental group 1: feeding embodiment 1 prepare containing the compositions of Cerebrolysin Vial, feeding amount with Cerebrolysin Vial in formula for contrast (1.5mg/kg body weight);
(3) experimental group 2: feeding embodiment 2 prepare containing the compositions of Cerebrolysin Vial, feeding amount with Cerebrolysin Vial in composite formula for contrast (1.5mg/kg body weight);
(4) experimental group 3: feeding embodiment 3 prepare containing the compositions of Cerebrolysin Vial, feeding amount with Cerebrolysin Vial in composite formula for contrast (1.5mg/kg body weight);
(5) contrast groups 1: compositions prepared by feeding embodiment 4, feeding amount is with the body weight of rat reference experimental group 3;
(6) contrast groups 2: feeding Cerebrolysin Vial, feeding amount is 1.5mg/kg body weight.
All experimental mouse are put experimental situation on pretreatment into and are familiar with experimental situation at least 1 hour, are now placed with two external wisps in experimental situation.
The experimental mouse of above-mentioned six groups is carried out feeding, and feeding starts experiment after 1 hour.
During experiment, experimental mouse is put into experimental situation, experimental mouse treats the sufficiently long time in experimental situation, the experimental mouse total time spent on two external wisps is made to be no less than for 10 seconds, then experimental mouse was left experimental situation after 3 hours, replace in two original external wisps with 1 new object, then experimental mouse is put into experimental situation, experimental mouse in experimental situation 5 minutes altogether, records them to new object (T
newly), past heritage body (T
old) the upper time spent, calculate the meansigma methods often organized.The time that experimental mouse spends on new object is longer, and illustrate that its memory is better, memory coefficient is defined as:
M=100 T
newly/ (T
newly+ T
old)
Result is as shown in table 1.
Table 1 healthy rat understanding experimental result
| Blank group | Experimental group 1 | Experimental group 2 | Experimental group 3 | Contrast groups 1 | Contrast groups 2 | |
| T Newly | 2.1±0.2 | 4.3±0.2 | 4.1±0.5 | 4.7±0.3 | 2.6±0.3 | 3.5±0.2 |
| T Old | 1.9±0.5 | 1.5±0.2 | 1.6±0.3 | 1.4±0.2 | 2.1±0.3 | 2.0±0.2 |
| M | 53 | 74 | 72 | 77 | 55 | 64 |
As can be seen from Table 1, the memory ability of the rat of contrast groups 1 (taking not containing the compositions of Cerebrolysin Vial) is organized very nearly the same with blank, the rat of contrast groups 2 (taking Cerebrolysin Vial merely) is compared with contrast groups 1 with blank group, its memory ability obviously increases, and experimental group 1, experimental group 2 and experimental group 3, namely take the rat of the present invention containing the compositions of Cerebrolysin Vial, its memory ability strengthens the most obvious, far away higher than other three groups.
Embodiment 5 is on the impact of cAMP cyclic AMP response element-binding protein concentration in brain
Public Mus hippocampus section (350 μm thick) of the WISTAR that experiment use two months is large, hippocampus section is poured into 95% oxygen and the saturated synthetic cerebrospinal fluid of 5% carbon dioxide at the temperature control intracavity of 30 DEG C.Hippocampus section recovery, after two hours, is divided into four groups, shown in specific as follows:
(1) blank group: do not use the hippocampus of any process to cut into slices;
(2) experimental group: the process of the compositions 5 μMs containing the Cerebrolysin Vial hippocampus section 15min adopting embodiment 3 to prepare;
(3) matched group 1: the compositions 5 μMs process hippocampus section 15min adopting embodiment 4 to prepare;
(4) matched group 2: adopt Cerebrolysin Vial 3 μMs process hippocampus section 15min;
After the hippocampus slicing treatment of four groups, hippocampus section uses liquid nitrogen freezing immediately.
Before test, be dissolved in cAMP after hippocampus section being dissolved and cushion in lysate.CAMP measures and adopts flicker to close on algoscopy, and total protein content uses BCA method to measure, and each data are the meansigma methods of three samples, and result is as shown in table 2.
The measurement result of table 2 cAMP content
As can be seen from Table 2, the compositions containing Cerebrolysin Vial of the present invention has very strong stimulation brain and the ability of learning capacity correlated activation.
Claims (1)
1., containing a compositions for Cerebrolysin Vial, it is characterized in that said composition is made up of each component of following parts by weight:
Cerebrolysin Vial 11 parts;
Radix Notoginseng total arasaponins 7 parts;
Ipratropium bromide 4 parts;
Betacyclodextrin 2 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410404033.2A CN104189036B (en) | 2014-08-16 | 2014-08-16 | Composition containing cerebroprotein hydrolysate and application of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410404033.2A CN104189036B (en) | 2014-08-16 | 2014-08-16 | Composition containing cerebroprotein hydrolysate and application of composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104189036A CN104189036A (en) | 2014-12-10 |
| CN104189036B true CN104189036B (en) | 2015-07-08 |
Family
ID=52074510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410404033.2A Active CN104189036B (en) | 2014-08-16 | 2014-08-16 | Composition containing cerebroprotein hydrolysate and application of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104189036B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101697988A (en) * | 2009-10-30 | 2010-04-28 | 重庆科瑞制药有限责任公司 | Taste hiding composition and application thereof in Xuesaitong chewable tablet |
| CN101732695A (en) * | 2008-11-20 | 2010-06-16 | 深圳四环医药有限公司 | Compound of brain protein hydrolyzate and maleic acid and method for preparing same |
| CN103393736A (en) * | 2013-04-12 | 2013-11-20 | 云南天秀植物科技开发有限公司 | Pharmaceutical composition for treating alzheimer disease and preparation method as well as application thereof |
-
2014
- 2014-08-16 CN CN201410404033.2A patent/CN104189036B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732695A (en) * | 2008-11-20 | 2010-06-16 | 深圳四环医药有限公司 | Compound of brain protein hydrolyzate and maleic acid and method for preparing same |
| CN101697988A (en) * | 2009-10-30 | 2010-04-28 | 重庆科瑞制药有限责任公司 | Taste hiding composition and application thereof in Xuesaitong chewable tablet |
| CN103393736A (en) * | 2013-04-12 | 2013-11-20 | 云南天秀植物科技开发有限公司 | Pharmaceutical composition for treating alzheimer disease and preparation method as well as application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104189036A (en) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Levy et al. | Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke | |
| US20200315997A1 (en) | C5 Ketone Compositions, and Related Methods, for Therapeutic and Performance Supplementation | |
| CN102552126B (en) | High-safety ropivacaine hydrochloride injection and preparation method thereof | |
| CN103145679B (en) | Preparation method and application of epigallocatechin gallate | |
| CN103102393B (en) | Polypeptide and application of polypeptide in preparation of drug used for treating depression | |
| CN104189036B (en) | Composition containing cerebroprotein hydrolysate and application of composition | |
| CN102631667B (en) | Nerve regeneration promotion injection and preparation method thereof | |
| CN1285334C (en) | Application of pinocembrin in preparing medication for treating disease relevant to hurt of nerve cell | |
| CN102813914B (en) | Medicinal composition used for treating or preventing cerebrovascular disease and related diseases | |
| CN101836997B (en) | Glycerol/fructose composite and preparation method thereof | |
| CN104069063A (en) | Hydroxyfasudil pharmaceutical composition and preparation method thereof | |
| CN1771992A (en) | Brain extract and its prepn and use | |
| CN1939357A (en) | Preparation of Ginkgo Damo injection | |
| CN104042645B (en) | Compound amino acid injection | |
| CN103385877B (en) | Taxol and cimetidine pharmaceutical composition | |
| CN103006550A (en) | Citicoline sodium injection and preparation method thereof | |
| CN1264506C (en) | Pharmaceutical combination containing red sage root element and preparation method thereof | |
| CN102757471B (en) | Novel active cytidine disodium triphosphate compound and pharmaceutical composition thereof | |
| CN1939328A (en) | Puerarin injection | |
| CN101024075A (en) | Use of ulinastatin for preparing medicine for treating and protecting multi-organ function injury | |
| CN1310635C (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1264519C (en) | Notoginseng total saponin amino acid transfusion liquid and its producing method | |
| TWI652057B (en) | Uses of resveratrol | |
| CN1293887C (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases, and preparation method thereof | |
| CN107261057B (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221114 Address after: No.6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone, Guangdong 510000 Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Patentee after: GUANGDONG ZERUI PHARMACEUTICAL Co.,Ltd. Patentee after: Guangzhou Lianrui Pharmaceutical Co.,Ltd. Patentee after: Guangzhou Runlin Pharmaceutical Technology Co.,Ltd. Patentee after: Euphorbia Biological Medicine Co.,Ltd. Address before: Building 1, No. 6, Dongbo Road, Guangzhou Economic and Technological Development Zone, Guangzhou, Guangdong 510765 Patentee before: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. |